# A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

> **NCT02988960** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 163 (actual)

## Conditions studied

- Advanced Solid Tumors Cancer

## Interventions

- **DRUG:** ABBV-927
- **DRUG:** ABBV-927
- **DRUG:** ABBV-181

## Key facts

- **NCT ID:** NCT02988960
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-02-22
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02988960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02988960, "A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02988960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*